TGFB1 and cancer: This underscores the need for a closer examination of FST as a potent and effective TGF-β antagonist that can be used to strategically target or prevent cancer cells from becoming resistant to the anti-proliferative effects of TGF-β and also to serve as a biomarker that can better stratify cancer patients and improve their responses to therapy.